208 related articles for article (PubMed ID: 8657123)
81. Decreased CP-1 (NF-Y) activity results in transcriptional down-regulation of topoisomerase IIalpha in a doxorubicin-resistant variant of human multiple myeloma RPMI 8226.
Wang H; Jiang Zg; Wong YW; Dalton WS; Futscher BW; Chan VT
Biochem Biophys Res Commun; 1997 Aug; 237(2):217-24. PubMed ID: 9268689
[TBL] [Abstract][Full Text] [Related]
82. Association of human DNA topoisomerase IIalpha with mitotic chromosomes in mammalian cells is independent of its catalytic activity.
Mo YY; Beck WT
Exp Cell Res; 1999 Oct; 252(1):50-62. PubMed ID: 10502399
[TBL] [Abstract][Full Text] [Related]
83. Down-regulation of human topoisomerase IIalpha expression correlates with relative amounts of specificity factors Sp1 and Sp3 bound at proximal and distal promoter regions.
Williams AO; Isaacs RJ; Stowell KM
BMC Mol Biol; 2007 May; 8():36. PubMed ID: 17511886
[TBL] [Abstract][Full Text] [Related]
84. Expression of drug resistance-related genes in head and neck squamous cell carcinomas and normal mucosa.
Hirata S; Katoh O; Oguri T; Watanabe H; Yajin K
Jpn J Cancer Res; 2000 Jan; 91(1):84-90. PubMed ID: 10744048
[TBL] [Abstract][Full Text] [Related]
85. Human topoisomerase IIalpha: targeting to subchromosomal sites of activity during interphase and mitosis.
Agostinho M; Rino J; Braga J; Ferreira F; Steffensen S; Ferreira J
Mol Biol Cell; 2004 May; 15(5):2388-400. PubMed ID: 14978217
[TBL] [Abstract][Full Text] [Related]
86. Decreased nucleotide excision repair activity and alterations of topoisomerase IIalpha are associated with the in vivo resistance of a P388 leukemia subline to F11782, a novel catalytic inhibitor of topoisomerases I and II.
Kruczynski A; Barret JM; Van Hille B; Chansard N; Astruc J; Menon Y; Duchier C; Créancier L; Hill BT
Clin Cancer Res; 2004 May; 10(9):3156-68. PubMed ID: 15131057
[TBL] [Abstract][Full Text] [Related]
87. Suppression of topoisomerase IIalpha expression and function in human cells decreases chromosomal radiosensitivity.
Terry SY; Riches AC; Bryant PE
Mutat Res; 2009 Apr; 663(1-2):40-5. PubMed ID: 19428368
[TBL] [Abstract][Full Text] [Related]
88. Protein kinase C delta activates topoisomerase IIalpha to induce apoptotic cell death in response to DNA damage.
Yoshida K; Yamaguchi T; Shinagawa H; Taira N; Nakayama KI; Miki Y
Mol Cell Biol; 2006 May; 26(9):3414-31. PubMed ID: 16611985
[TBL] [Abstract][Full Text] [Related]
89. Topoisomerase IIalpha and other drug resistance markers in advanced non-small cell lung cancer.
Dingemans AC; van Ark-Otte J; Span S; Scagliotti GV; van der Valk P; Postmus PE; Giaccone G
Lung Cancer; 2001 May; 32(2):117-28. PubMed ID: 11325482
[TBL] [Abstract][Full Text] [Related]
90. Temporal and spatial distribution of DNA topoisomerase II alters during proliferation, differentiation, and apoptosis in HL-60 cells.
Sugimoto K; Yamada K; Egashira M; Yazaki Y; Hirai H; Kikuchi A; Oshimi K
Blood; 1998 Feb; 91(4):1407-17. PubMed ID: 9454772
[TBL] [Abstract][Full Text] [Related]
91. The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues.
Turley H; Comley M; Houlbrook S; Nozaki N; Kikuchi A; Hickson ID; Gatter K; Harris AL
Br J Cancer; 1997; 75(9):1340-6. PubMed ID: 9155056
[TBL] [Abstract][Full Text] [Related]
92. Evaluation of topotecan and etoposide for non-Hodgkin lymphoma: correlation of topoisomerase-DNA complex formation with clinical response.
Kancherla RR; Nair JS; Ahmed T; Durrani H; Seiter K; Mannancheril A; Tse-Dinh YC
Cancer; 2001 Feb; 91(3):463-71. PubMed ID: 11169927
[TBL] [Abstract][Full Text] [Related]
93. Localisation of DNA topoisomerase IIalpha in mouse erythroleukemia cells.
Ivanova EC; Donev RM; Djondjurov LP
Mol Cells; 1999 Jun; 9(3):309-13. PubMed ID: 10420991
[TBL] [Abstract][Full Text] [Related]
94. Glucose-regulated protein 75 overexpression attenuates ionizing radiation-mediated injury in PC12 cells by inducing the expression of topoisomerase IIα.
Guo W; Yang L; Li H; Xie Z; Liu W; Zuo J
Mol Med Rep; 2012 Dec; 6(6):1423-7. PubMed ID: 22965249
[TBL] [Abstract][Full Text] [Related]
95. Changes in the stability of a human H3 histone mRNA during the HeLa cell cycle.
Morris TD; Weber LA; Hickey E; Stein GS; Stein JL
Mol Cell Biol; 1991 Jan; 11(1):544-53. PubMed ID: 1986245
[TBL] [Abstract][Full Text] [Related]
96. Periodic expression of nuclear and mitochondrial DNA replication genes during the trypanosomatid cell cycle.
Pasion SG; Brown GW; Brown LM; Ray DS
J Cell Sci; 1994 Dec; 107 ( Pt 12)():3515-20. PubMed ID: 7706402
[TBL] [Abstract][Full Text] [Related]
97. SUMOylation of the C-terminal domain of DNA topoisomerase IIα regulates the centromeric localization of Claspin.
Ryu H; Yoshida MM; Sridharan V; Kumagai A; Dunphy WG; Dasso M; Azuma Y
Cell Cycle; 2015; 14(17):2777-84. PubMed ID: 26131587
[TBL] [Abstract][Full Text] [Related]
98. Evidence for post-transcriptional regulation of cyclin B1 mRNA in the cell cycle and following irradiation in HeLa cells.
Maity A; McKenna WG; Muschel RJ
EMBO J; 1995 Feb; 14(3):603-9. PubMed ID: 7859748
[TBL] [Abstract][Full Text] [Related]
99. The cytotoxicity of benzaldehyde nitrogen mustard-2-pyridine carboxylic acid hydrazone being involved in topoisomerase IIα inhibition.
Fu Y; Zhou S; Liu Y; Yang Y; Sun X; Li C
Biomed Res Int; 2014; 2014():527042. PubMed ID: 24995306
[TBL] [Abstract][Full Text] [Related]
100. Regulation of histone mRNA in the unperturbed cell cycle: evidence suggesting control at two posttranscriptional steps.
Harris ME; Böhni R; Schneiderman MH; Ramamurthy L; Schümperli D; Marzluff WF
Mol Cell Biol; 1991 May; 11(5):2416-24. PubMed ID: 2017161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
